Icon

VIZIMPRO (nda211288)- (15MG,30MG,45MG)

DACOMITINIB PFIZER
15MG,30MG,45MG
No No
2028-Aug-26 2023-Sep-27
None None
None No
VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
0 0 0
Total Other Developers None
Drugs with Suitability No
15MG ** ** - - -
30MG ** ** - - -
45MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.